Targeting HO-1 as a therapeutic strategy against chronic pain
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-07 · 399 (10) · 14677-14704
DOI: 10.1007/s00210-026-05340-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 28.04.2026. Verfasst von Shuchun Zeng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangz…. Hauptthemen laut MEDLINE: Heme Oxygenase-1, Chronic Pain, Anti-Inflammatory Agents. Die Arbeit nennt 196 Literaturangaben. Gefördert von: Project of Public Welfare Technology Research in Zhejiang Province.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Chronic pain, a leading global health issue, severely compromises patients' quality of life. Its complex pathogenesis involves peripheral and central sensitization processes and is closely associated with a series of inflammatory and oxidative stress (OS) responses. Heme oxygenase-1 (HO-1), a key antioxidant enzyme that extensively regulates cellular OS and inflammatory responses, holds promising therapeutic potential for chronic pain due to its significant anti-inflammatory and neuroprotective effects. This review systematically explores the pathogenesis of chronic pain, detailing its pathological progression, describing the physicochemical properties of HO-1 with emphasis on its anti-inflammatory and antioxidant characteristics, and summarizing multiple regulatory pathways. Challenges in the field, including potential toxic side effects of HO-1 revealed in some studies, are also highlighted. Finally, potential therapeutic drugs targeting HO-1 for chronic pain treatment from 2020 to 2026 are compiled, aiming to provide new perspectives and references for future therapeutic strategies and clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, China.
- Pengpu Xincun Community Health Service Center, Shanghai, 200435, China.
- Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, China. februarydan@zstu.edu.cn.
Förderung
- Project of Public Welfare Technology Research in Zhejiang Province
Zitieren
APA
Zeng, S., Zheng, L., Wang, K., & Wang, D. (2026). Targeting HO-1 as a therapeutic strategy against chronic pain. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(10), 14677-14704. https://doi.org/10.1007/s00210-026-05340-7
Vancouver
Zeng S, Zheng L, Wang K, Wang D. Targeting HO-1 as a therapeutic strategy against chronic pain. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(10):14677-14704. doi:10.1007/s00210-026-05340-7
BibTeX
@article{Zeng2026,
author = {Zeng, Shuchun and Zheng, Lubin and Wang, Kaixuan and Wang, Dan},
title = {Targeting HO-1 as a therapeutic strategy against chronic pain},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {10},
pages = {14677--14704},
doi = {10.1007/s00210-026-05340-7}
}
EUVIMED